Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disorder and Circadian Rhythm Modulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MTNR1B drug discovery. For complex GPCR targets, we strongly recommend lentivirus-based stable cell lines to preserve native membrane conformation and glycosylation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Recommended) | MTNR1B Promise-ORF / Lentivirus Premade Particles. Full-length ORF (NM_001350258.2) for stable cell lines. High titer (>10^8 TU/mL). Essential for GPCR screening. | View MTNR1B Products |
| Antigen | MTNR1B Full-length ORF Lentivirus. HEK293 expressed, preserves native glycosylation and 7-TM topology. Sequence Verified. | View MTNR1B Products |
| Mutant Protein | MTNR1B ECD / Mutant Protein (e.g., variants rs8192552). High purity (>95%), Endotoxin <1 EU/ug. | View MTNR1B Products |
| Benchmark Ab | Anti-MTNR1B Reference Antibody. Recombinant positive control for binding assays and FACS verification. | View MTNR1B Products |
| Validator | MTNR1B siRNA Set. For knockdown verification and specificity controls. | View MTNR1B Products |
| Related Target A | MTNR1A. Melatonin receptor family member; critical for selectivity screening vs MTNR1B. | View MTNR1A Products |
| Related Target B | RORA. Nuclear receptor in melatonin signaling pathway; synergistic target for metabolic regulation. | View RORA Products |
| Related Target C | GPR50. Orphan GPCR known to heterodimerize with MTNR1B; modulates receptor pharmacology. | View GPR50 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-mediated stable expression in HEK293/CHO preserves native glycosylation and 7-TM topology for functional assays. |
| Ortholog Cross-species Evaluation | Human/Mouse/Rat MTNR1B ORF variants available with sequence verification for preclinical translation. |
| Subfamily Counter Screening (MT1 vs MT2) | Homolog panel proteins (MTNR1A, MTNR1B) strictly verified by sequencing; custom stable cell lines available. |
| Lack of Controls / False Positives | Validated siRNA and clinical benchmark antibodies included for assay standardization and background reduction. |
Live MTNR1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Key Mutations and Variants
MTNR1B genetic variants are strongly linked to type 2 diabetes risk. The following mutations in dbSNP have been characterized and require specific reagents for functional studies:
| dbSNP ID | Variant Name (UniProt) | Evidence |
|---|---|---|
| rs8192552 | P49286 VAR_009262 | Missense mutation; impacts receptor activity. |
| rs370338802 | P49286 VAR_009263 | Rare variant associated with altered signaling. |
| rs8192553 | P49286 VAR_049421 | Known polymorphism; used in population studies. |
These variants can be incorporated into expression constructs for selectivity and functional validation assays.
Global Clinical Landscape & Future Outlook
The race for MTNR1B (Melatonin Receptor Type 1B, MT2) therapeutics is evolving from traditional non-selective MT1/MT2 agonists (e.g., Ramelteon, Tasimelteon) for sleep disorders toward highly selective modulators for metabolic diseases. Genome-wide association studies (GWAS) consistently link MTNR1B variants to impaired insulin secretion and type 2 diabetes. The next R&D wave focuses on biased signaling modulators that uncouple glucose regulation from sleep cycle effects. Developers are exploring selective antagonists and allosteric modulators, requiring stringent selectivity and conformational assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists (non-selective) | Takeda, Vanda | Insomnia, Circadian Disorders | Selectivity Assay (Need MT1/MT2 stable cell lines via Lentivirus) |
| Small Molecule Antagonists | Roche, Early Stage Biotech | Type 2 Diabetes, Metabolic Syndrome | cAMP / Calcium Flux Assay (Need sequence-verified full-length MTNR1B overexpression) |
| Biased Agonist | Specialized Biotech | Metabolic Syndrome (β-arrestin vs cAMP pathway) | β-arrestin Recruitment vs cAMP Pathway Selectivity (Need conformationally intact receptor) |
| Allosteric Modulators | Academia, CNS Bio | Neuropathic Pain, Mood Disorders | Conformational validation (Cell-based receptor signaling) |
| Antibody/Peptide | Emerging Biotech | Sleep Disorders, Peripheral Metabolism | Binding Kinetics (Need high-purity extracellular domain analogs) |
Related Targets Overview
- MTNR1A: The closest homolog; mandatory counter-screen for selectivity. Expressed mainly in brain (sleep regulation).
- RORA: Nuclear receptor involved in circadian rhythm and metabolic gene regulation; potential for combination therapy.
- GPR50: Orphan GPCR that heterodimerizes with MTNR1B; modulates receptor trafficking and signaling; important for advanced mechanistic studies.